Off-label use of SGLT-2 inhibitors in type 1 diabetes should be taken very cautiously, and some recommended daily monitoring of ketones in the blood or urine [7], which is hard to carry out in the real world (the mechanism of SGLT-2 inhibitor-associated EDKA is illustrated in Figure 2). This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.